Blog

Infliximab was the first antibody for IBD. Biointron reviews its approval, mechanism, and impact on advancing therapeutic monoclonal antibodies.

B cells are central to immunity. Biointron explains how they generate antibodies, defend against pathogens, and contribute to therapeutic development.

Abinvivo delivers in vivo antibody products for research and development. Biointron showcases their differentiation, applications, and benefits for discovery programs.

Engineering CDR loops boosts binding strength. Biointron outlines strategies to optimize CDRs for developing potent therapeutic antibodies.

CDRs define antibody specificity. Biointron highlights their crucial role in binding antigens and driving therapeutic antibody design and optimization.

Antigens are molecular structures that trigger immune recognition. Biointron explains how antibodies detect them, guiding research and therapeutic discovery.

Biointron’s Antibody ABCs video series makes complex science simple, educating researchers and students on antibody basics, formats, and functions in an engaging way.

Afucosylation boosts ADCC activity. Biointron outlines this glycoengineering strategy that enhances antibody potency and clinical outcomes.

Somatic hypermutation drives high-affinity antibodies. Biointron explains its role in B cell evolution and therapeutic antibody optimization.

ADCC directs immune cells to kill targets. Biointron explains how this mechanism underpins therapeutic antibody efficacy in oncology and virology.

Immuno-oncology harnesses immunity to fight cancer. Biointron explores how antibodies reshape oncology through immune system activation.

ADCs unite antibody targeting with potent payloads. Biointron explains their mechanisms and importance in advancing cancer therapeutics.